MYOZYME (alglucosidase alfa)
METABOLIC DISEASE ENZYME REPLACEMENT, POMPE DISEASE · LYSOSOMAL ALPHA-1,4-GLUCOSIDASE DEFICIENCY
GENZYME
Drug class
Metabolic Disease Enzyme Replacement, Pompe Disease
Metabolic Disease Enzyme Replacement, Pompe Disease is a compendial and formulary therapeutic classification that encompasses exogenous enzyme therapies specifically designated to treat Pompe disease, also known as glycogen storage disease type II. Read more about Metabolic Disease Enzyme Replacement, Pompe Disease
4 drugs in this class 2 manufacturers
Drugs in Metabolic Disease Enzyme Replacement, Pompe Disease
LUMIZYME (alglucosidase alfa)
METABOLIC DISEASE ENZYME REPLACEMENT, POMPE DISEASE · LYSOSOMAL ALPHA-1,4-GLUCOSIDASE DEFICIENCY
GENZYME
NEXVIAZYME (avalglucosidase alfa-ngpt)
METABOLIC DISEASE ENZYME REPLACEMENT, POMPE DISEASE · LYSOSOMAL ALPHA-1,4-GLUCOSIDASE DEFICIENCY
GENZYME
POMBILITI (cipaglucosidase alfa-atga)
METABOLIC DISEASE ENZYME REPLACEMENT, POMPE DISEASE · LYSOSOMAL ALPHA-1,4-GLUCOSIDASE DEFICIENCY
AMICUS THERAPEU
Filter & compare in the drug finder →
Opens the drug finder with Metabolic Disease Enzyme Replacement, Pompe Disease preselected. Add indication or manufacturer filters there.
Metabolic Disease Enzyme Replacement, Pompe Disease is a compendial and formulary therapeutic classification that encompasses exogenous enzyme therapies specifically designated to treat Pompe disease, also known as glycogen storage disease type II.
Agents in this class—such as recombinant human acid alpha-glucosidase formulations—function by supplying the deficient lysosomal enzyme, which is internalized by cells via mannose-6-phosphate receptors to degrade pathological intralysosomal glycogen deposits.
Consequently, this therapeutic category is primarily indicated to manage both infantile-onset and late-onset forms of Pompe disease, helping prevent or slow progressive cardiomyopathy, respiratory insufficiency, and skeletal muscle degradation.
-
mclarenhealthplan.org
Metabolic Disease Enzyme Replacement, Pompe Disease is a compendial and formulary therapeutic classification that encompasses exogenous enzyme therapies specifically designated to treat Pompe disease, also known as glycogen storage disease type II
-
redsailtechnologies.com
Metabolic Disease Enzyme Replacement, Pompe Disease is a compendial and formulary therapeutic classification that encompasses exogenous enzyme therapies specifically designated to treat Pompe disease, also known as glycogen storage disease type II
-
nih.gov
Metabolic Disease Enzyme Replacement, Pompe Disease is a compendial and formulary therapeutic classification that encompasses exogenous enzyme therapies specifically designated to treat Pompe disease, also known as glycogen storage disease type II Agents in this class—such as recombinant human acid alpha-glucosidase formulations—function by supplying the deficient lysosomal enzyme, which is internalized by cells via mannose-6-phosphate receptors to degrade pathological intralysosomal glycogen de...
-
nih.gov
Agents in this class—such as recombinant human acid alpha-glucosidase formulations—function by supplying the deficient lysosomal enzyme, which is internalized by cells via mannose-6-phosphate receptors to degrade pathological intralysosomal glycogen deposits
-
tandfonline.com
Agents in this class—such as recombinant human acid alpha-glucosidase formulations—function by supplying the deficient lysosomal enzyme, which is internalized by cells via mannose-6-phosphate receptors to degrade pathological intralysosomal glycogen deposits Consequently, this therapeutic category is primarily indicated to manage both infantile-onset and late-onset forms of Pompe disease, helping prevent or slow progressive cardiomyopathy, respiratory insufficiency, and skeletal muscle degradati...
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.